Hints and tips:
...jobs (FT) Fed fines Deutsche Bank $186mn over failure to fix control flaws (FT) US banks under pressure as corporate depositors demand higher rates (FT) Macquarie takes further control of Britain’s gas network...
...In 2007, just as Facebook was taking off, she built a social network in her spare time to connect the CEOs of tech start-ups — a kind of primitive LinkedIn....
...News Corp releases fiscal-year results, while Porsche publishes results for the first half. Quarterly earnings are also due for NTT Group and BioNTech....
...Its $300m investment in oncology drug developer Relay Therapeutics is now worth $1.4bn following its IPO last summer....
...Its $300m investment in oncology drug developer Relay Therapeutics is now worth more than $1bn following its July listing....
...Other companies in its Vision Fund portfolio are eyeing a public listing, including DoorDash, the lossmaking US food delivery start-up, and oncology drug developer Relay Therapeutics....
...That puts them “at the forefront of collaborators’ minds when it comes to novel therapeutics”. The Jenner Institute’s choice will not make or break either company....
...A health network in Pennsylvania uses our video conferencing platform to communicate with patients most vulnerable to Covid-19....
...It focuses on oncology, cardiovascular, surgical anaesthetics and endocrine therapeutic treatments....
...Oncology-related M&A is very hot at the moment....
...It weakened alliances, networks, programmes and services....
...In the most candid and detailed comments so far on the embarrassing setback, Nadim Ahmed, president of haematology and oncology at Celgene, said officials at the FDA were “actually quite surprised” to receive...
...GSK has set up a global network of roughly 50 research collaborations in bioelectronics with academic teams and small biotech companies....
...The group snapped up CanniMed Therapeutics five months ago and previously invested in the public listing of The Green Organic Dutchman, a cannabis producer....
...Sanofi said it would pay $11.6bn for the haemophilia specialist Bioverativ, a 63 per cent premium, while Celgene agreed to pay $9bn for Juno Therapeutics, a cellular therapy company — almost two times as...
...Bruno Strigini, chief executive of oncology at the Swiss drugmaker, said: “We carefully considered the appropriate price and looked at many factors, including the medical and clinical value.”...
...“Our aim is to build Europe’s leading oncology company....
...Andrew Conrad, chief executive of Verily, said the partnership would “help European life sciences innovators accelerate patient and physician access to new and promising therapeutics”....
...Oncology is the discipline embracing epigenetics with the greatest enthusiasm, as a potential diagnostic and therapeutic tool....
...The trial involved a Seattle-based company called Juno Therapeutics, whose early backers included Jeff Bezos, founder of Amazon....
...Celgene, one of the biggest names in the US biotech industry, has invested $1bn in Juno Therapeutics, as part of a wide-ranging partnership that is seen as a strong vote of confidence in a new generation...
...In hot pursuit of Novartis are the US biotech companies Kite Pharma and Juno Therapeutics....
...“Quite a lot of studies are needed to identify the best treatment,” said Dr Molyneux, head of the paediatric oncology ward at Queen Elizabeth Hospital, who is collaborating with a growing network of international...
...Analysts at Nomura said the potential combination looks attractive, but cautioned investors on the likely integration risks: “Running separate networks with separate technologies makes achieving network...
...The third distinctive subsector is implantable and disposable therapeutic devices. Israeli companies have distinguished themselves in the areas of cardiovascular, orthopedic, and dental devices....
International Edition